KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Deferred Taxes: 2015-2019

Historic Deferred Taxes for Arbutus Biopharma (ABUS) over the last 5 years, with Dec 2019 value amounting to -$12.7 million.

  • Arbutus Biopharma's Deferred Taxes fell 195.68% to -$12.7 million in Q3 2019 from the same period last year, while for Sep 2019 it was -$81.5 million, marking a year-over-year decrease of 16.72%. This contributed to the annual value of -$12.7 million for FY2019, which is 195.68% down from last year.
  • According to the latest figures from FY2019, Arbutus Biopharma's Deferred Taxes is -$12.7 million, which was down 195.68% from -$4.3 million recorded in FY2018.
  • In the past 5 years, Arbutus Biopharma's Deferred Taxes ranged from a high of -$4.3 million in FY2018 and a low of -$105.1 million during FY2016.
  • In the last 3 years, Arbutus Biopharma's Deferred Taxes had a median value of -$12.7 million in 2019 and averaged -$13.8 million.
  • Its Deferred Taxes has fluctuated over the past 5 years, first crashed by 549.13% in 2016, then skyrocketed by 82.39% in 2018.
  • Over the past 5 years, Arbutus Biopharma's Deferred Taxes (Yearly) stood at -$16.2 million in 2015, then plummeted by 549.13% to -$105.1 million in 2016, then spiked by 76.85% to -$24.3 million in 2017, then skyrocketed by 82.39% to -$4.3 million in 2018, then slumped by 195.68% to -$12.7 million in 2019.